CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.
ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.
.
Pro Medicus remains under algo engine buy conditions after rallying from the November entry level at $30.
The current retracement from $50 to $41 means investors should now be watching the short-term momentum indicators for a turn higher. We continue to like the long-term growth profile of Pro Medicus.
For more detail on the strategy, please call our office on 1300 614 002.
CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.
ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.
.
ASX:IZZ is under Algo Engine buy conditions. We expect buying interest to increase within the $55 – $60 price range.
Traders may wait for the third factor to align, an upturn in the momentum indicators. Watch for the stochastic to move higher or the price action on the main chart to cross above the 10-day average.
WOW:ASX is under Algo Engine buy conditions and is a current holding on our ASX model portfolio.
Post demerger Endeavour Drinks will own the largest network of retail alcohol stores in Australia with 1,630 stores. It will also have 332 hotels and 12,400 electronic gaming machines across 1,775 liquor licences.
Endeavour operates across two divisions, Retail and Hotels. Forcast FY22 revenue is likely to be around $10.5bn and EBIT $700m.
WOW shareholders will receive one new Endeavour Group share for every WOW share held at the demerger record date (25-June). Post the demerger WOW will likely consider the potential for capital management of $1.6bn-$2bn.
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.
CIMIC is a high risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.
24/4 CIMIC breaks above the 10-day average after forming a new trend low mid-week at $16.86.
10/5 Dec 21 $20 call options are now trading at $1.10.
ASX:IZZ is under Algo Engine buy conditions. We expect buying interest to increase within the $55 – $60 price range.
10/5 Traders may wait for the third factor to align, an upturn in the momentum indicators. Watch for the stochastic to move higher or the price action on the main chart to cross above the 10-day average.
CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.
ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.
.
Qube Holdings is under Algo Engine buy conditions, with price support at $2.90. Consider a stop-loss on a break below the support.
In 2021, container port freight volumes are up on average 10 to 20% per month compared to last year.
Since writing the above post, QUB has found steady buying interest above the $2.90 support and the momentum indicators continue to trend higher.
A number of institutions have upgraded their price targets into the $3.40 to $3.60 range.
8/5 Buy Qube Holdings and consider a stop loss below $2.90.
Level 17 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453
Or start a free thirty day trial for our full service, which includes our ASX Research.